Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyproheptadine is a first-generation antihistamine and serotonin antagonist used primarily to treat allergic symptoms such as sneezing, runny nose, itching, red or watery eyes, and other manifestations of seasonal allergies. It is also used for appetite stimulation and has off-label uses in the treatment of serotonin syndrome and certain types of headaches, including migraines. Cyproheptadine acts as a potent competitive antagonist at both histamine H1 receptor and several serotonin (5-HT) receptors. Its antagonism at the hypothalamic appetite center may explain its ability to stimulate appetite. Additionally, it exhibits anticholinergic and sedative effects and has been reported to block calcium channels at the pituitary level.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyproheptadine.